Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Identifieur interne : 001B72 ( PubMed/Corpus ); précédent : 001B71; suivant : 001B73Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Auteurs : Yohichi Kumaki ; Craig W. Day ; Miles K. Wandersee ; Bradley P. Schow ; Justin S. Madsen ; Dixon Grant ; Jason P. Roth ; Donald F. Smee ; Lawrence M. Blatt ; Dale L. BarnardSource :
- Biochemical and biophysical research communications [ 1090-2104 ] ; 2008.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Bronchi (virology), Cell Line, Cell Line, Tumor, Humans, Interferon Type I (pharmacology), Interferon Type I (therapeutic use), Interferon-alpha, Recombinant Proteins, Respiratory Mucosa (virology), SARS Virus (drug effects), SARS Virus (physiology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Interferon Type I.
- chemical , therapeutic use : Antiviral Agents, Interferon Type I.
- drug effects : SARS Virus, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- virology : Bronchi, Respiratory Mucosa, Severe Acute Respiratory Syndrome.
- Animals, Cell Line, Cell Line, Tumor, Humans, Interferon-alpha, Recombinant Proteins.
Abstract
The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.
DOI: 10.1016/j.bbrc.2008.04.006
PubMed: 18406349
Links to Exploration step
pubmed:18406349Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</title><author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name><affiliation><nlm:affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name></author><author><name sortKey="Wandersee, Miles K" sort="Wandersee, Miles K" uniqKey="Wandersee M" first="Miles K" last="Wandersee">Miles K. Wandersee</name></author><author><name sortKey="Schow, Bradley P" sort="Schow, Bradley P" uniqKey="Schow B" first="Bradley P" last="Schow">Bradley P. Schow</name></author><author><name sortKey="Madsen, Justin S" sort="Madsen, Justin S" uniqKey="Madsen J" first="Justin S" last="Madsen">Justin S. Madsen</name></author><author><name sortKey="Grant, Dixon" sort="Grant, Dixon" uniqKey="Grant D" first="Dixon" last="Grant">Dixon Grant</name></author><author><name sortKey="Roth, Jason P" sort="Roth, Jason P" uniqKey="Roth J" first="Jason P" last="Roth">Jason P. Roth</name></author><author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name></author><author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M" last="Blatt">Lawrence M. Blatt</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18406349</idno><idno type="pmid">18406349</idno><idno type="doi">10.1016/j.bbrc.2008.04.006</idno><idno type="wicri:Area/PubMed/Corpus">001B72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</title><author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name><affiliation><nlm:affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name></author><author><name sortKey="Wandersee, Miles K" sort="Wandersee, Miles K" uniqKey="Wandersee M" first="Miles K" last="Wandersee">Miles K. Wandersee</name></author><author><name sortKey="Schow, Bradley P" sort="Schow, Bradley P" uniqKey="Schow B" first="Bradley P" last="Schow">Bradley P. Schow</name></author><author><name sortKey="Madsen, Justin S" sort="Madsen, Justin S" uniqKey="Madsen J" first="Justin S" last="Madsen">Justin S. Madsen</name></author><author><name sortKey="Grant, Dixon" sort="Grant, Dixon" uniqKey="Grant D" first="Dixon" last="Grant">Dixon Grant</name></author><author><name sortKey="Roth, Jason P" sort="Roth, Jason P" uniqKey="Roth J" first="Jason P" last="Roth">Jason P. Roth</name></author><author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name></author><author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M" last="Blatt">Lawrence M. Blatt</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author></analytic><series><title level="j">Biochemical and biophysical research communications</title><idno type="eISSN">1090-2104</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Bronchi (virology)</term><term>Cell Line</term><term>Cell Line, Tumor</term><term>Humans</term><term>Interferon Type I (pharmacology)</term><term>Interferon Type I (therapeutic use)</term><term>Interferon-alpha</term><term>Recombinant Proteins</term><term>Respiratory Mucosa (virology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Interferon Type I</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon Type I</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Bronchi</term><term>Respiratory Mucosa</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Cell Line, Tumor</term><term>Humans</term><term>Interferon-alpha</term><term>Recombinant Proteins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18406349</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN><JournalIssue CitedMedium="Internet"><Volume>371</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation></Journal><ArticleTitle>Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</ArticleTitle><Pagination><MedlinePgn>110-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2008.04.006</ELocationID><Abstract><AbstractText>The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumaki</LastName><ForeName>Yohichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Wandersee</LastName><ForeName>Miles K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Schow</LastName><ForeName>Bradley P</ForeName><Initials>BP</Initials></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Justin S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Dixon</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Jason P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Smee</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Blatt</LastName><ForeName>Lawrence M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Barnard</LastName><ForeName>Dale L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 AI015435</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-A1-30048</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AI-15354</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>56588OP40D</RegistryNumber><NameOfSubstance UI="C050739">interferon alfacon-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020545" MajorTopicYN="N">Respiratory Mucosa</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>04</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18406349</ArticleId><ArticleId IdType="pii">S0006-291X(08)00661-X</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2008.04.006</ArticleId><ArticleId IdType="pmc">PMC2441846</ArticleId><ArticleId IdType="mid">NIHMS51641</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Aug;79(15):9470-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16014910</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hepatology. 1997 Sep;26(3):747-54</Citation><ArticleIdList><ArticleId IdType="pubmed">9303508</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2006 Aug;71(1):53-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16621037</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Gene Ther. 2006 Mar;13(6):532-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16177819</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12947028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Respir Med. 2003 Apr;97(4):382-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12693798</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):268-73</Citation><ArticleIdList><ArticleId IdType="pubmed">13465721</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2006 Jun;87(Pt 6):1691-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16690935</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1064-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14519241</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(6):3846-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15731278</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2006 Feb;69(2):70-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16337697</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Investig Drugs. 2004 Feb;5(2):179-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15043392</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Respir Cell Mol Biol. 2004 Mar;30(3):251-60</Citation><ArticleIdList><ArticleId IdType="pubmed">14969997</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):293-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12892961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hepatology. 1998 Apr;27(4):1136-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9537455</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Invest New Drugs. 1990 Nov;8(4):347-54</Citation><ArticleIdList><ArticleId IdType="pubmed">2084068</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2005 Jun;66(2-3):99-102</Citation><ArticleIdList><ArticleId IdType="pubmed">15911026</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Chem Chemother. 2004 Jan;15(1):15-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15074711</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67</Citation><ArticleIdList><ArticleId IdType="pubmed">13465720</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001B72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:18406349
|texte= Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18406349" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |